All In Biotech

Drug Trial Radar · NCT03679143

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

A Phase 1 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1273 and the Effect of Food on ZSP1273 Pharmacokinetics in Chinese Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Aug 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

103

Actual

Start

Sep 20, 2018

Primary completion

Mar 19, 2019

Study completion Apr 26, 2019

Sponsor

Sponsor type
Industry
First posted
Sep 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center,double-blind,randomized,parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of ZSP1273,and the effect of food on ZSP1273 Pharmacokinetics.

Conditions

  • Influenza

Interventions

  • ZSP1273 100 mgDrug

    ZSP1273 tablet administered orally once daily under fasted condition

  • Placebo 100 mgDrug

    Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.

  • ZSP1273 200 mgDrug

    ZSP1273 tablets administered orally once daily under fasted condition

  • Placebo 200 mgDrug

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

  • ZSP1273 400 mgDrug

    ZSP1273 tablets administered orally once daily in the fasting state

  • Placebo 400 mgDrug

    Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

  • ZSP1273 600 mgDrug

    ZSP1273 tablets administered orally once daily under fasted condition

  • Placebo 600 mgDrug

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

  • ZSP1273 900 mgDrug

    ZSP1273 tablets administered orally once daily in the fasting state

  • Placebo 900 mgDrug

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

  • ZSP1273 1200 mgDrug

    ZSP1273 tablets administered orally once daily in the fasting state

  • Placebo 1200 mgDrug

    Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

  • ZSP1273Drug

    ZSP1273 tablets administered orally once daily under fasted or fed condition

  • PlaceboDrug

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition

  • ZSP1273 Low DoseDrug

    ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.

  • PlaceboDrug

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.

  • ZSP1273 Median DoseDrug

    ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

  • PlaceboDrug

    Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

  • ZSP1273 High DoseDrug

    ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

  • PlaceboDrug

    Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)Time frame: At day 5, 9, 12 days post first dosing for SAD, MAD, FE part respectively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.